Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ImmunityBio Inc has a consensus price target of $18.19 based on the ratings of 4 analysts. The high is $30 issued by D. Boral Capital on November 12, 2024. The low is $4.75 issued by Piper Sandler on August 19, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital, EF Hutton, and Piper Sandler on November 12, 2024, October 23, 2024, and August 19, 2024, respectively. With an average price target of $21.58 between D. Boral Capital, EF Hutton, and Piper Sandler, there's an implied 333.40% upside for ImmunityBio Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for ImmunityBio (NASDAQ:IBRX) was reported by D. Boral Capital on November 12, 2024. The analyst firm set a price target for $30.00 expecting IBRX to rise to within 12 months (a possible 502.41% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for ImmunityBio (NASDAQ:IBRX) was provided by D. Boral Capital, and ImmunityBio maintained their buy rating.
There is no last upgrade for ImmunityBio
The last downgrade for ImmunityBio Inc happened on May 12, 2023 when Piper Sandler changed their price target from $10 to $4 for ImmunityBio Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunityBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunityBio was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.
While ratings are subjective and will change, the latest ImmunityBio (IBRX) rating was a maintained with a price target of $30.00 to $30.00. The current price ImmunityBio (IBRX) is trading at is $4.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.